RightFit
RecruitingPhase not listed

Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

EXERT-BCHC: Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
20 Years to 89 Years
Sex
Female only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study compares four supervised group strength-training plans for women who have been treated for breast cancer. It tests how these plans affect fitness, muscle growth, and body fat.

This study investigates the impact of four standard of care, monitored group exercise regimens (resistance training) on conditioning and hypertrophy in women previously treated for breast cancer. The study will compare two conditioning regimens (6-12-25 and 8x8) and two hypertrophy regimens (5/5/5 cluster sets and double training) to assess changes in VO2 max, muscle mass, and fat mass.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Women ages 20 to 89.
  • Have been prescribed exercise as part of usual care.
  • Have breast cancer confirmed by a tissue sample: DCIS (cancer within milk ducts) or invasive cancer (cancer that has spread into nearby breast tissue).
  • Have had breast cancer treatment, such as surgery, radiation, chemotherapy, immune therapy, or hormone therapy.
  • Are not currently receiving chemotherapy. Immune therapy or targeted cancer drugs are allowed.
  • Have more than 6 months of strength-training experience guided by a certified strength and conditioning specialist (CSCS).

Who can't join

  • Currently receiving cell-killing chemotherapy for breast cancer.
  • The study doctor finds that group strength training would not be safe for you.
  • Have severe arthritis or a joint, heart, blood vessel, muscle, or bone condition that the study doctor finds makes strength training unsafe.
  • Take beta blockers or medicines listed as GLP-1 inhibitors.
  • Are pregnant.
  • Are male.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: 1. Age 20-89 years 2. Women prescribed exercise as a Standard of Care 3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast 4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. 5. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed. 6. Women with \> 6 months of resistance training experience under expert guidance by a CSCS Exclusion Criteria: 1. Any current treatment with cytotoxic chemotherapy for breast cancer 2. Inability to safely engage in group sessions of resistance training as deemed by study Pl 3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by Pl to be unsafe to engage in resistance training 4. Beta blocker or GLP-1 inhibitor medications 5. Pregnant women 6. Males

Study sites (1)

PA